”Old” Novo drug to take center stage in Tresiba launch
If US authorities decide to approve Novo Nordisk’s diabetes drug Tresiba, it could have a huge impact on one of the group’s current best-selling products. The question is how Novo Nordisk will react.
BY BENJAMIN WERNER CHRISTENSEN
Whether or not Novo Nordisk has learned from the challenges for its global rival Sanofi shall remain unsaid, but – according to Nordea analyst Michael Novod – the Danish-based drug group is not about to sacrifice its high-grossing diabetes drug Levemir, if it wins approval for its newest blockbuster contender, Tresiba. The conclusion is made in a new 51-page report from the bank.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo resubmits Tresiba application
For abonnenter
Novo’s handpicked dozen to decide Tresiba’s fate
For abonnenter
Novo edges closer to Tresiba approval
For abonnenter
